OICR enters collaboration with Janssen Inc. in the development of multi-centre
clinical trials to identify improved prostate cancer biomarkers
TORONTO, April 22, 2013 /CNW/ - Dr. Tom Hudson, President and Scientific
Director of the Ontario Institute for Cancer Research (OICR) today announced a
collaboration with Janssen Inc. to find and test new biomarkers to identify
patients with hormone resistant prostate cancer at high risk for disease
progression and biomarkers of response to therapy. These biomarkers could lead
to more personalized treatments and fewer side effects for prostate cancer
"This collaboration will further advance the world-class research in prostate
cancer already underway in Ontario," said Dr. Hudson. "We are happy to partner
with Janssen on this project in the hope of providing patients diagnosed with
prostate cancer better and more precise treatment options."
"Today's announcement will see some of Ontario's most talented researchers
working together to improve the lives of patients diagnosed with prostate
cancer," said Reza Moridi, Ontario Minister of Research and Innovation. "Our
government is working to make Ontario a place where this type of innovative
partnership can flourish - both advancing knowledge and helping to strengthen
The project will be led by OICR's High Impact Clinical Trials Program in
collaboration with researchers in Toronto, Hamilton, London and Ottawa. OICR
and its research partners will leverage the province's expertise in genomics,
circulating tumour cells and molecular imaging to establish up to three
multi-centre clinical trials in Ontario. The trials could last for up to three
"With improved biomarkers doctors can better differentiate those patients with
aggressive prostate cancer from those with non-aggressive prostate cancer and
those patients that are responding to treatments from those that are not,"
said Dr. Janet Dancey, Director of OICR's High Impact Clinical Trials Program.
"This means we could better tailor therapy to the individual patient and
potentially spare many men from the serious side effects associated with
prostate cancer treatment, while also finding improved ways to treat men with
more aggressive disease."
Specific objectives of the project include evaluating the similarity between
archived diagnostic samples, serial samples of circulating tumour cells and
recent tumour biopsies, using next generation sequencing to correlate
molecular profiles with outcomes in patients with hormone resistant prostate
cancer and evaluating new imaging probes to assess tumour burden in patients
and better determine response to treatment.
Prostate cancer is the most common cancer among Canadian men, excluding
non-melanoma skin cancer. An estimated 26,500 men are diagnosed with prostate
cancer and 4,000 will die of the disease each year. Hormone resistant prostate
cancer refers to prostate cancer that has become resistant to hormone therapy.
This usually occurs within one to three years after the start of treatment.
Finding new biomarkers will allow doctors to determine which patients with
hormone resistant prostate cancer are at risk of rapid progression and which
are not, allowing doctors to better tailor treatments to individual patients
and monitor their progression more precisely.
The Ontario Institute for Cancer Research
OICR is an innovative cancer research and development institute dedicated to
prevention, early detection, diagnosis and treatment of cancer. The Institute
is an independent, not-for-profit corporation, supported by the Government of
Ontario. The annual budget for OICR, its research partners and collaborators
exceeds $150 million. This supports more than 1,600 investigators, clinician
scientists, research staff and trainees located at its headquarters and in
research institutes and academia across the Province of Ontario. OICR has key
research efforts underway in small molecules, biologics, stem cells, imaging,
genomics, informatics and bio-computing. For more information, please visit
the website atwww.oicr.on.ca
Contact: Hal Costie Senior Communications Officer
Email:email@example.com Telephone: 647-260-7921 Mobile: 647-963-5289
SOURCE: Ontario Institute for Cancer Research
To view this news release in HTML formatting, please use the following URL:
CO: Ontario Institute for Cancer Research
NI: HEA HEA VNT
-0- Apr/22/2013 14:00 GMT
Press spacebar to pause and continue. Press esc to stop.